Back to Search Start Over

The mutational landscape of ocular marginal zone lymphoma identifies frequent alterations in TNFAIP3 followed by mutations in TBL1XR1 and CREBBP

Authors :
Daeun Ryu
Woong-Yang Park
Seok Jin Kim
Hae Yong Yoo
Kyeong Kyu Kim
Hyunchul Jung
Jae Won Yun
Sejoon Lee
So-Hyun Shin
Ambarnil Ghosh
Sang Cheol Kim
Jae Yong Nam
Seung Ho Lee
Jung Kyoon Choi
Je-Gun Joung
Young Hyeh Ko
Won Seog Kim
Source :
Oncotarget
Publication Year :
2017
Publisher :
Impact Journals, LLC, 2017.

Abstract

Ocular marginal zone lymphoma is a common type of low-grade B-cell lymphoma. To investigate the genomic changes that occur in ocular marginal zone lymphoma, we analyzed 10 cases of ocular marginal zone lymphoma using whole-genome and RNA sequencing and an additional 38 cases using targeted sequencing. Major genetic alterations affecting genes involved in nuclear factor (NF)-κB pathway activation (60%), chromatin modification and transcriptional regulation (44%), and B-cell differentiation (23%) were identified. In whole-genome sequencing, the 6q23.3 region containing TNFAIP3 was deleted in 5 samples (50%). In addition, 5 structural variation breakpoints in the first intron of IL20RA located in the 6q23.3 region was found in 3 samples (30%). In targeted sequencing, a disruptive mutation of TNFAIP3 was the most common alteration (54%), followed by mutations of TBL1XR1 (18%), cAMP response element binding proteins (CREBBP) (17%) and KMT2D (6%). All TBL1XR1 mutations were located within the WD40 domain, and TBL1XR1 mutants transfected into 293T cells increased TBL1XR1 binding with nuclear receptor corepressor (NCoR), leading to increased degradation of NCoR and the activation of NF-κB and JUN target genes. This study confirms genes involving in the activation of the NF-kB signaling pathway is the major driver in the oncogenesis of ocular MZL.

Details

ISSN :
19492553
Volume :
8
Database :
OpenAIRE
Journal :
Oncotarget
Accession number :
edsair.doi.dedup.....4b01f4c258bc963a7ec3cc8bef5db40a
Full Text :
https://doi.org/10.18632/oncotarget.14928